US FDA approves Prism's first product, Nexterone
This article was originally published in Scrip
Executive Summary
Prism Pharmaceuticals' first product, Nexterone, a new formulation of the anti-arrhythmic, amiodarone, has been approved for marketing in the US. It is also the first product using CyDex Pharmaceuticals' Captisol technology to be approved there.